The Wire
Surgeries & Interventions September 23, 2022
Aggressive LDL Reduction Strategy September 23, 2022
A new study shows aggressive in-hospital PCSK-9 therapy (plus statins) for heart attack patients would likely mean fewer deaths and cardiovascular events.
Surgeries & Interventions September 21, 2022
Renal Denervation’s Comeback September 21, 2022
While previous studies may have fallen short and more research might be needed, physicians and regulators can have renewed confidence that Medtronic’s Symplicity system and ReCor’s Paradise device lower blood pressure.
Preventive Cardiology September 15, 2022
Is HFpEF an Exercise Deficiency Syndrome? September 15, 2022
Thinking of HFpEF as an exercise deficiency syndrome will help physicians better understand the condition, recognize risk earlier, and most importantly, provide a clear path to prevention.
More Stories
Cardiology Pharmaceuticals September 14, 2022
Polypill’s Simplicity Advantage September 14, 2022
A study in NEJM found that heart attack patients who took a “polypill” (a 3-part cocktail of aspirin, ramipril, and atorvastatin) had a lower risk of major CV events. But findings from the SECURE trial also left some docs scratching their heads.
Cardiovascular Disease Solutions September 11, 2022
GRACE 3.0: Correcting the Default Male Risk September 11, 2022
A Lancet-published study tackled the limitations of the GRACE 2.0 heart attack mortality risk score – namely, the systematic underestimation of mortality risk in female patients.
Surgeries & Interventions September 2, 2022
Medtronic’s Defibrillation Innovation September 2, 2022
A new era of implantable cardioverter-defibrillators (ICDs) may be on the horizon.
Surgeries & Interventions August 31, 2022
PCI Fizzles in REVIVED Study August 31, 2022
The highly anticipated REVIVED trial found that percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe ventricular dysfunction.
Guidelines August 28, 2022
Statin Guidelines Spark Debate August 28, 2022
The new USPSTF statin recommendations sparked debate last week, eliciting four editorials published the same day in the JAMA journal family.
Cardiovascular Disease August 24, 2022
Obesity Paradox Bias August 24, 2022
New findings suggest it is worse to be normal weight than to have a BMI in the obese range. Does this track? One thought leader warns of collider bias—a subtype of selection bias—within the study.
Cardiac Imaging August 21, 2022
Echo Clues: When to Suspect Amyloidosis August 21, 2022
Routine echocardiographic parameters may prove to be “the key” to spotting cardiac amyloidosis in the presence of aortic stenosis.
Cardiology Guidelines August 17, 2022
Algorithm Aversion in HF Care August 17, 2022
In this heart failure clinical trial, Yale researchers found that providing clinicians with 1-year mortality risk estimates did not improve patient outcomes nor influence decision-making.
Cardiogenetics August 12, 2022
For Genetic Tests, Size Matters August 12, 2022
In contrast to typical practice, it appears that more comprehensive genetic panels produce meaningful insights that could guide physician decision-making. When it comes to testing for cardiomyopathies and arrhythmias, the added burden of uncertainty may be worth enduring.
Cardiovascular Disease August 10, 2022
Heating Up: Two Heart Medications May Increase Risk August 10, 2022
Antiplatelet medications and beta blockers can improve survival and quality of life for people with cardiovascular disease. But those protections may come with added risk on hot summer days.
Surgeries & Interventions August 5, 2022
Physiological Pacing Movement Gains Momentum August 5, 2022
Physiological pacing has witnessed tremendous growth in the last ten years, and new funding may provide the evidence physicians need to make it the heart failure standard of care.
Cardiology Pharmaceuticals August 3, 2022
Alnylam’s Promising Heart Failure Treatment August 3, 2022
Alnylam's Onpattro achieved the primary endpoint in its high-stakes APOLLO-B study for transthyretin amyloid cardiomyopathy.
Cardiogenetics July 29, 2022
Why Men Die Earlier July 29, 2022
A study published in Science found that the loss of the Y chromosome, which occurs naturally in many men as they age, can cause heart scarring and premature death.
Cardiology Guidelines July 27, 2022
Rosuvastatin, Kidney Risks, and a Clinical Takeaway July 27, 2022
New research from Johns Hopkins further confirms that rosuvastatin use may increase the risk of kidney damage, especially at higher doses.
Cardiology Business July 24, 2022
Cardiac Tests & Procedures Cost Variability July 24, 2022
A new JAMA study found substantial cost variations in common cardiovascular tests and procedures across top US hospitals.
Cardiovascular Disease July 20, 2022
Race and Cardiovascular Health July 20, 2022
Two papers revealed considerable gaps in cardiovascular mortality between Black and White adults, despite improving trends overall.
Cardiology Business July 15, 2022
Medtronic and CathWorks Partner on FFRangio July 15, 2022
Medtronic is tightening its ties to CathWorks through a $75M investment while laying the groundwork for a future acquisition.
Preventive Cardiology July 13, 2022
New Findings Reignite REDUCE-IT Concerns July 13, 2022
The cardiology community is revisiting the high-impact and controversial REDUCE-IT study in light of new evidence that suggests the study’s placebo, mineral oil, is harmful.
